Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

Dapagliflozin delivers cardiometabolic benefits in patients with myocardial infarction, regardless of their baseline A1c ...

Dapagliflozin significantly reduced the risk of all-cause mortality or worsening heart failure by 28% in high-risk patients undergoing transcatheter aortic valve implantation (TAVI).

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

PHILADELPHIA, PA—Dapagliflozin added to optimal medical therapy results in meaningful improvements in symptoms and health-related quality of life in heart failure patients with reduced ejection ...

The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a ...

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...

During follow-up, the primary outcome occurred in 16.4% of participants in the dapagliflozin group and 19.5% of participants in the placebo group, for an HR of 0.82 (95% CI, 0.73-0.92; P < .001).

"Dapagliflozin inhibits renal glucose reabsorption, promotes urinary excretion, and works independently of insulin action of secretion," Dr. Henry said during the presentation.

Dapagliflozin—a drug that improves glycemic control by increasing urinary excretion of glucose—is both safe and effective for the treatment of type 2 diabetes mellitus (T2DM), according to the ...